Suppr超能文献

环孢素治疗的移植肾功能良好的肾移植受者的低剂量类固醇疗法。加拿大多中心移植研究组。

Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group.

作者信息

Sinclair N R

机构信息

Canadian Centre for Transplant Studies, University Hospital, London, Ont.

出版信息

CMAJ. 1992 Sep 1;147(5):645-57.

Abstract

OBJECTIVE

Low-dose prednisone given on alternate days as a steroid adjunct to cyclosporine therapy was investigated primarily for its influence on kidney graft and patient survival and, secondarily, on renal function and complications.

DESIGN

Multicentre randomized double-blind clinical trial.

SETTING

Fourteen Canadian transplant centres.

PATIENTS

A total of 523 patients with well-functioning renal transplants (cadaveric grafts or grafts from living related donors) and without active graft rejection reactions who were entered into the trial from 1982 to 1985.

INTERVENTION

Patients were randomly assigned 90 days after transplantation to receive either placebo (260 patients) or low-dose prednisone (263 patients).

MAIN OUTCOME MEASURES

Graft and patient survival.

MAIN RESULTS

After at least 5 years of follow-up 50 patients assigned placebo had lost their graft and 17 had died; the corresponding figures for those assigned prednisone were 38 and 16. After an average interval of 1.4 years 143 patients in the placebo group and 123 patients in the prednisone group had stopped therapy with the test drug or had had their treatment group decoded or both. Patients were withdrawn from the study 2 years after stopping the test therapy. The actuarial 5-year graft survival rates were 73% and 85% in the placebo and prednisone groups respectively (p = 0.03), and the actuarial 5-year patient survival rates were 92% and 94% respectively (p = 0.6). This analysis included 43 and 29 graft losses and 14 and 12 deaths in the placebo and prednisone groups respectively. Weibull parametric modelling of graft survival identified the following variables as risk factors for graft loss: histocompatibility leukocyte antigen B (HLA-B) mismatching (p = 0.007), donor death from cerebrovascular accident (p = 0.01), increased donor age (p = 0.02) and being a male recipient (p = 0.05). When these factors were included in the Cox proportional hazards model, the influence of assigned treatment on graft survival was reduced to p = 0.1. Donor death from cerebrovascular accident (p = 0.002), diabetes mellitus in the recipient (p = 0.02) and increased recipient age (p = 0.05) were risk factors for patient death. Renal function and incidence of complications were similar in the treatment groups.

CONCLUSIONS

Continued administration of low-dose prednisone on alternate days is advisable, particularly in patients with cadaveric grafts and those with previously failed transplants.

摘要

目的

主要研究隔日给予小剂量泼尼松作为环孢素治疗的类固醇辅助药物对肾移植及患者存活的影响,其次研究其对肾功能和并发症的影响。

设计

多中心随机双盲临床试验。

地点

14个加拿大移植中心。

患者

1982年至1985年共523例肾功能良好的肾移植患者(尸体供肾或亲属活体供肾),且无移植排斥反应。

干预

移植后90天患者被随机分配接受安慰剂(260例患者)或小剂量泼尼松(263例患者)治疗。

主要观察指标

移植肾和患者的存活情况。

主要结果

至少随访5年后,接受安慰剂治疗的50例患者移植肾失功,17例死亡;接受泼尼松治疗的相应数字分别为38例和16例。平均间隔1.4年后,安慰剂组143例患者和泼尼松组123例患者停止试验药物治疗或治疗组编码被破解或两者皆有。停止试验治疗2年后患者退出研究。安慰剂组和泼尼松组的5年移植肾存活精算率分别为73%和85%(p = 0.03),5年患者存活精算率分别为92%和94%(p = 0.6)。该分析包括安慰剂组和泼尼松组分别有43例和29例移植肾失功以及14例和12例死亡。移植肾存活的威布尔参数模型确定以下变量为移植肾失功的危险因素:组织相容性白细胞抗原B(HLA - B)错配(p = 0.007)、供体死于脑血管意外(p = 0.01)、供体年龄增加(p = 0.02)以及受者为男性(p = 0.05)。当将这些因素纳入Cox比例风险模型时,分配治疗对移植肾存活的影响降至p = 0.1。供体死于脑血管意外(p = 0.002)、受者患有糖尿病(p = 0.02)以及受者年龄增加(p = 0.05)是患者死亡的危险因素。治疗组的肾功能和并发症发生率相似。

结论

建议隔日持续给予小剂量泼尼松,特别是对于尸体供肾移植患者和既往移植失败的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e5ad/1336386/208059f23b53/cmaj00258-0090-a.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验